AIDS Treatment News - FDA approves two combination pills, Epzicom and Truvada; comment on commercial race to once-a-day nucleosides
July 23, 2004 -- On August 2, 2004, the U.S. FDA approved once-daily combination antiretroviral pills from two companies: GlaxoSmithKline's Epzicom (Ziagen [abacavir]...
Independent, The (London) - GSK Aids drug faces FDA safety review
March 28, 2008 -- Business News IN BRIEF *The US drug regulator is reviewing the safety of an Aids drug sold by GlaxoSmithKline after a study showed a higher...
HealthDay - Test Detects Sensitivity to HIV Drug
February 6, 2008 -- New research suggests that an expensive blood test could help a small minority of HIV patients discover whether they should avoid a common AIDS drug...
Business Wire - Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA® in Europe
December 11, 2007 -- PRINCETON, N.J. & FOSTER CITY, Calif. -- Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences, Inc. (Nasdaq:GILD) today announced an...
Business Wire - European CHMP Issues Positive Opinion for ATRIPLA
October 18, 2007 -- -- Once Granted by the European Commission, ATRIPLA Would Represent the First And Only Once-Daily Single Tablet Regimen for Many HIV/AIDS Patients in...
Business Wire - Health Canada Approves ATRIPLA® , the First Once-Daily Single Tablet Regimen for HIV
October 17, 2007 -- Product Developed Through Joint Venture Between Bristol-Myers Squibb Company and Gilead Sciences, the First of Its Kind in HIV Treatment PRINCETON,...
Business Wire - Merck & Co., Inc. To Distribute ATRIPLA™ in Developing Countries
February 16, 2007 -- New once-daily, single tablet combination regimen may simplify HIV treatment and care Not-for-profit price to poorest countries and those hardest...
Business Wire - 96-Week Data From Gilead's Study 934 Comparing Viread® and Emtriva® to Combivir® Both in Combination With Sustiva® Published in Journal of...
December 15, 2006 -- FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced the publication of 96-week data from an ongoing clinical trial, Study 934,...
Business Wire - Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA™ to European Medicines Agency
October 9, 2006 -- PRINCETON, N.J. & FOSTER CITY, Calif. & WHITEHOUSE STATION, N.J. -- Bristol-Myers Squibb Company (NYSE:BMY), Gilead Sciences, Inc....
Business Wire - Gilead Sciences and Merck Establish Agreement for Distribution of ATRIPLA™ in Developing Countries
August 11, 2006 -- FOSTER CITY, Calif. & WHITEHOUSE STATION, N.J. -- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck & Co., Inc. (NYSE: MRK) today announced that...
